Hepatitis C seroprevalence among intravenous drug users in Tehran

Journal of Research in Medical Sciences

Volumn 13, Issue 6, 2008, Pages 295-302

  Mir Nasseri, Mohammad Mahdi ^a   Poustchi, Hossein ^a   Nasseri Moghadam, Siavosh ^a   Tavakkoli, Hamid ^b,c   Mohammadkhani, Ashraf ^a   Afshar, Parviz ^a   Malekzadeh, Reza ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hepatitis C; Intravenous drug abuse; Prison

Indexed keywords

COCAINE; DIAMORPHINE; HEPATITIS C ANTIBODY; MORPHINE;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG DEPENDENCE TREATMENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; INTRAVENOUS DRUG ABUSE; IRAN; MAJOR CLINICAL STUDY; MALE; PRISONER; QUESTIONNAIRE; SEROPREVALENCE; SEXUAL BEHAVIOR; SYRINGE;

EID: 63249108807     PISSN: 17351995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Pradat P, Trepo C. HCV: epidemiology, modes of transmission and prevention of spread. Baillieres Best Pract Res Clin Gastroenterol 2000; 14(2):201-210.
2. Patti AM, Santi AL, Pompa MG, Giustini C, Vescia N, Mastroeni I et al. Viral hepatitis and drugs: a continuing problem. Int J Epidemiol 1993; 22(1):135-139.
3. Darwish MA, Faris R, Darwish N, Shouman A, Gadallah M, El Sharkawy MS et al. Hepatitis c and cirrhotic liver disease in the Nile delta of Egypt: a community-based study. Am J Trop Med Hyg 2001; 64(3-4):147-153.
4. Conry-Cantilena C, VanRaden M, Gibble J, Melpolder J, Shakil AO, Viladomiu. L et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334(26):1691-1696.
5. Haley RW, Fischer RP. Commercial tattooing as a potentially important source of hepatitis C infection. Clinical epidemiology of 626 consecutive patients unaware of their hepatitis C serologic status. Medicine (Baltimore) 2001; 80(2):134-151.
6. Ridzon R, Gallagher K, Ciesielski C, Ginsberg MB, Robertson BJ, Luo CC et al. Simultaneous transmission of human immunodeficiency virus and hepatitis C virus from a needle-stick injury. N Engl J Med 1997; 336(13):919-922.
7. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341(8):556-562.
8. Allwright S, Bradley F, Long J, Barry J, Thornton L, Parry JV. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey. BMJ 2000; 321(7253):78-82.
9. Crofts N, Stewart T, Hearne P, Ping XY, Breshkin AM, Locarnini SA. Spread of bloodborne viruses among Australian prison entrants. BMJ 1995; 310(6975):285-288.
10. Oliveira ML, Bastos FI, Telles PR, Yoshida CF, Schatzmayr HG, Paetzold U et al. Prevalence and risk factors for HBV, HCV and HDV infections among injecting drug users from Rio de Janeiro, Brazil. Braz J Med Biol Res 1999; 32(9):1107-1114.
11. van B, I, Dwyer R, Dore GJ, Luo K, Kaldor JM. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study. BMJ 1998; 317(7156):433-437.
12. Gaube J, Feucht HH, Laufs R, Polywka S, Fingscheidt E, Muller BE. [Hepatitis A, B and C as desmoteric infections]. Gesundheitswesen 1993; 55(5):246-249.
13. Stark K, Schreier E, Muller R, Wirth D, Driesel G, Bienzle U. Prevalence and determinants of anti-HCV seropositivity and of HCV genotype among intravenous drug users in Berlin. Scand J Infect Dis 1995; 27(4):331-337.
14. Bell J, Batey RG, Farrell GC, Crewe EB, Cunningham AL, Byth K. Hepatitis C virus in intravenous drug users. Med J Aust 1990; 153(5):274-276.
15. Alter MJ. The epidemiology of acute and chronic hepatitis C. Clin Liver Dis 1997; 1(3):559-vii.
16. Francis DP, Hadler SC, Prendergast TJ, Peterson E, Ginsberg MM, Lookabaugh C et al. Occurrence of hepatitis A, B, and non-A/non-B in the United States. CDC sentinel county hepatitis study I. Am J Med 1984; 76(1):69-74.
17. Mokri A. Brief overview of the status of drug abuse in Iran. Arch Iranian Med 2002; 5(3):184-90.
18. Zali MR, Aghazadeh R, Nourouzi A, Amirrasouli H. Anti-HCV antibody among Iranian IV Drug users: It it a serious problem? Arch Iranian Med 2000; 4:115-9.
19. Christensen PB, Krarup HB, Niesters HG, Norder H, Georgsen J. Prevalence and incidence of bloodborne viral infections among Danish prisoners. Eur J Epidemiol 2000; 16(11):1043-1049.
20. Love A, Sigurdsson JR, Stanzeit B, Briem H, Rikardsdottir H, Widell A. Characteristics of hepatitis C virus among intravenous drug users in Iceland. Am J Epidemiol 1996; 143(6):631-636.
21. Yamakawa Y, Sata M, Suzuki H, Noguchi S, Tanikawa. K. Higher elimination rate of hepatitis C virus among women. J Viral Hepat 1996; 3(6)317-321.
22. Butler T, Spencer J, Cui J, Vickery K, Zou J, Kaldor J. Seroprevalence of markers for hepatitis B, C and G in male and female prisoners-NSW, 1996. Aust N Z J Public Health 1999; 23(4):377-384.
23. Tibbs CJ. Methods of transmission of hepatitis C. J Viral Hepat 1995; 2(3):113-119.
24. Des J, Friedman SR, Choopanya K, Vanichseni S, Ward TP. International epidemiology of HIV and AIDS among injecting drug users. AIDS 1992; 6(10): 1053-1068.
25. Levine OS, Vlahov D, Nelson KE. Epidemiology of hepatitis B virus infections among injecting drug users: sero-prevalence, risk factors, and viral interactions. Epidemiol Rev 1994; 16(2):418-436.
26. Camacho LM, Brown BS, Simpson DD. Psychological dysfunction and HIV/AIDS risk behavior. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11 (2):198-202.
27. Thomas DL, Vlahov D, Solomon L, Cohn S, Taylor E, Garfein R et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995; 74(4):212-220.
28. Hedouin V, Gosset D. [Infection with hepatitis C virus in a prison environment. A prospective study in Loos-lez-Lille, France]. Gastroenterol Clin Biol 1998; 22(1):55-58.
29. Crofts N, Hopper JL, Bowden DS, Breschkin AM, Milner R, Locarnini SA. Hepatitis C virus infection among a cohort of Victorian injecting drug users. Med J Aust 1993; 159(4):237-241.
30. Donoghoe MC, Stimson GV, Dolan KA. Sexual behaviour of injecting drug users and associated risks of HIV infection for non-injecting sexual partners. AIDS Care 1989; 1(1):51-58.
31. Weild AR, Gill ON, Bennett D, Livingstone SJ, Parry JV, Curran L. Prevalence of HIV, hepatitis B, and hepatitis C antibodies in prisoners in England and Wales: a national survey. Commun Dis Public Health 2000; 3(2):121-126.
32. Mohtasham AZ, Rezvani M, Jafari SR, Jafari SA. Prevalence of hepatitis C virus infection and risk faptors of drug using prisoners in Guilan province. East Mediterr Health J 2007; 13(2):250-256.
33. Zamani S, Ichikawa S, Nassirimanesh B, Vazirian M, Ichikawa K, Gouya NM, et al. Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. Int J Drug Policy 2007; 18(5):359-363.